Exposure to Potentially Dangerous Drug-Drug Interactions Involving Antipsychotics
Supplemental Material
1080_ds001.pdf (91 KB)
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.
Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
×1080_ds001.pdf (91 KB)
This project received educational grant support from Ortho-McNeil Janssen Scientific Affairs, L.L.C. The authors thank William H. Olson, C.V. Damaraju, Steve Ascher, Riad Dirani, Jessica M. Panish, and George Wong for their invaluable suggestions and support regarding research design and data analysis techniques, and they appreciate the comments of colleagues at the University of Cincinnati Medical Center.
Dr. Wu was employed by Johnson & Johnson at the time of this research . Dr. Jing, a graduate student at the time of this research, is an employee of Bristol-Myers Squibb and owns stock in the company. Dr. Keck is a paid consultant to the advisory board of Bristol-Myers Squibb and to Pamlab and is a coinventor (U.S. patent 6,387,956) of a method of tramadol administration for treatment of obsessive-compulsive spectrum disorder. He has received no financial gain from this patent. Dr. Patel receives grant support or is under contract to AstraZeneca, Janssen Scientific Affairs, and Pfizer, Inc. The other authors report no competing interests.